Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SALVIANOLIC ACID B | ? unclear | Mechanistic | DGIdb | |
| CANDOXATRIL | ? unclear | Mechanistic | DGIdb | |
| CILAZAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| TP0556351 | ↓ inhibits | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| SILDENAFIL | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| RESCINNAMINE | ? unclear | Mechanistic | DGIdb | |
| SPIRAPRIL | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ARGIPRESSIN | ? unclear | Mechanistic | DGIdb | |
| METOPROLOL | ? unclear | Mechanistic | DGIdb | |
| DELAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| ACETYLCHOLINE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| IMIDAPRIL | ↓ inhibits | Mechanistic | DGIdb | |
| MALATHION | ↓ inhibits | Mechanistic | DGIdb | |
| MOEXIPRIL | ? unclear | Mechanistic | 56.0 nM (IC50) | DGIdb |
| VORINOSTAT | ? unclear | Mechanistic | DGIdb | |
| ILEPATRIL | ↓ inhibits | Mechanistic | DGIdb | |
| RXP470.1 | ↓ inhibits | Mechanistic | DGIdb | |
| CGS-27023A | ? unclear | Mechanistic | DGIdb | |
| NITROPRUSSIDE | ? unclear | Mechanistic | DGIdb | |
| ENALAPRILAT ANHYDROUS | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | DGIdb |
| TORSEMIDE | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| FOSINOPRIL | ? unclear | Mechanistic | DGIdb | |
| FUROSEMIDE | ? unclear | Mechanistic | DGIdb | |
| TEMOCAPRIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENAZEPRIL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARBARIL | ↓ inhibits | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUINAPRIL | ? unclear | Mechanistic | 8.3 nM (IC50) | DGIdb |
| COMPOUND 1 [PMID: 24900526] | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 20 [PMID: 22153340] | ↓ inhibits | Mechanistic | DGIdb | |
| BUMETANIDE | ? unclear | Mechanistic | DGIdb | |
| GALLOPAMIL | ? unclear | Mechanistic | DGIdb | |
| FLUOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AZD6605 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 229 agents ranked by evidence tier.
AGTR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CANDESARTAN CILEXETIL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586135 | ? unclear | Mechanistic | DGIdb | |
| VALSARTAN | ↓ inhibits | Mechanistic | 4700.0 nM (Ki) | DGIdb |
| EPROSARTAN MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| FIMASARTAN | ↓ inhibits | Mechanistic | DGIdb | |
| ASCORBIC ACID | ? unclear | Mechanistic | DGIdb | |
| OLMESARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| AZILSARTAN MEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC ANDROSTANOLONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL347610 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL421088 | ? unclear | Mechanistic | DGIdb | |
| LOSARTAN POTASSIUM | ↓ inhibits | Mechanistic | 5.5 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL1492017 | ? unclear | Mechanistic | DGIdb | |
| SPARSENTAN | ↓ inhibits | Mechanistic | DGIdb | |
| SODIUM CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL261693 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1972216 | ? unclear | Mechanistic | DGIdb | |
| EPROSARTAN | ? unclear | Mechanistic | 7.3 nM (IC50) | DGIdb |
| C-FOS ANTISENSE | ? unclear | Mechanistic | DGIdb | |
| SARALASIN ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| IRBESARTAN | ↓ inhibits | Mechanistic | 1.1 nM (Ki) | DGIdb |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| SAPRISARTAN | ? unclear | Mechanistic | DGIdb | |
| H2O2 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL591834 | ? unclear | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL400912 | ? unclear | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| IDOXIFENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL528694 | ? unclear | Mechanistic | DGIdb | |
| IL-6 | ? unclear | Mechanistic | DGIdb | |
| ANGIOTENSIN II ACETATE | ↑ activates | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| GAMMA-INTERFERON | ? unclear | Mechanistic | DGIdb | |
| AZILSARTAN KAMEDOXOMIL | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1445650 | ? unclear | Mechanistic | DGIdb | |
| MUSCLE RELAXANT | ? unclear | Mechanistic | DGIdb | |
| CL-329167 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 249 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| JNJ1661010 | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb | |
| LY2077855 | ↓ inhibits | Mechanistic | DGIdb | |
| OL135 | ↓ inhibits | Mechanistic | DGIdb | |
| WARFARIN | ? unclear | Mechanistic | DGIdb | |
| ASP8477 | ↓ inhibits | Mechanistic | DGIdb | |
| URB597 | ↓ inhibits | Mechanistic | DGIdb | |
| ROSUVASTATIN | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DESIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| BIVALIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| PEGMUSIRUDIN | ? unclear | Mechanistic | DGIdb | |
| FLOVAGATRAN | ? unclear | Mechanistic | DGIdb | |
| ANISINDIONE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| CATECHIN | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | DGIdb | |
| ODIPARCIL | ? unclear | Mechanistic | DGIdb | |
| DPOC-4088 | ? unclear | Mechanistic | DGIdb | |
| LUSUTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| ICHORCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PYRIDOXAL PHOSPHATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| BORTEZOMIB | ? unclear | Mechanistic | 13000.0 nM (Ki) | DGIdb |
| ANTITHROMBIN ALFA | ↓ inhibits | Mechanistic | DGIdb | |
| SR-123781A | ? unclear | Mechanistic | DGIdb | |
| ENOXAPARIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| CYANIDIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586628 | ? unclear | Mechanistic | DGIdb | |
| AZD-8165 | ? unclear | Mechanistic | DGIdb | |
| STAUROSPORINE | ↓ inhibits | Mechanistic | DGIdb | |
| AVATROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| HIRUDIN | ? unclear | Mechanistic | DGIdb | |
| CYANIN | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 2C [PMID: 24900538] | ↓ inhibits | Mechanistic | DGIdb | |
| SILIBININ | ? unclear | Mechanistic | DGIdb | |
| EP-217609 | ? unclear | Mechanistic | DGIdb | |
| APRAMIDE A | ? unclear | Mechanistic | DGIdb | |
| EPICATECHIN | ? unclear | Mechanistic | DGIdb | |
| ARGATROBAN | ↓ inhibits | Mechanistic | DGIdb | |
| MELAGATRAN | ? unclear | Mechanistic | 4700.0 nM (IC50) | DGIdb |
| ATECEGATRAN METOXIL | ↓ inhibits | Mechanistic | DGIdb | |
| ASPIRIN TRELAMINE | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| XIMELAGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1083499 | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE | ? unclear | Mechanistic | Open Targets |
Showing top 40 of 238 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
ITGB3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| EPTIFIBATIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ATN-161 | ↓ inhibits | Mechanistic | DGIdb | |
| ABCIXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYPATE | ? unclear | Mechanistic | DGIdb | |
| INTETUMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| INTEGRIN RECEPTOR ANTAGONIST GLPG0187 | ? unclear | Mechanistic | DGIdb | |
| ZALUNFIBAN | ↓ inhibits | Mechanistic | DGIdb | |
| CILENGITIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ANTI-THYMOCYTE GLOBULIN | ? unclear | Mechanistic | DGIdb | |
| TIROFIBAN HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ABITUZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TIROFIBAN | ? unclear | Mechanistic | DGIdb | |
| GANTOFIBAN | ? unclear | Mechanistic | DGIdb | |
| ETARACIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TADOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb |
LDLR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| GLUCAGON (RDNA) | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| COLESTIPOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN CALCIUM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL233611 | ? unclear | Mechanistic | DGIdb | |
| TRIBUTYRIN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TRANSFORMING GROWTH FACTOR | ? unclear | Mechanistic | DGIdb | |
| CHOLESTYRAMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| EPOETIN ALFA | ? unclear | Mechanistic | DGIdb | |
| TETRACYCLINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| MIPOMERSEN | ? unclear | Mechanistic | DGIdb | |
| PHYTOESTROGEN | ? unclear | Mechanistic | DGIdb | |
| ANTIVIRAL AGENT | ? unclear | Mechanistic | DGIdb | |
| FAT EMULSION | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| SOY PROTEIN ISOLATE | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| BUTYRIC ACID | ? unclear | Mechanistic | DGIdb | |
| ACTH | ? unclear | Mechanistic | DGIdb | |
| ALIROCUMAB | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ACETYLCYSTEINE | ? unclear | Mechanistic | DGIdb | |
| ROSUVASTATIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| EVINACUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL114890 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL114705 | ↑ activates | Mechanistic | 1200.0 nM (EC50) | ChEMBL |
| CHEMBL115304 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL324616 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL115205 | ↑ activates | Mechanistic | 4000.0 nM (EC50) | ChEMBL |
| CHEMBL112449 | ↑ activates | Mechanistic | 1000.0 nM (EC50) | ChEMBL |
| CHEMBL419400 | ↑ activates | Mechanistic | 7000.0 nM (EC50) | ChEMBL |
| CHEMBL419763 | ↑ activates | Mechanistic | 1700.0 nM (EC50) | ChEMBL |
| CHEMBL419042 | ↑ activates | Mechanistic | 2000.0 nM (EC50) | ChEMBL |
Showing top 40 of 48 agents ranked by evidence tier.
NOS3
Pipeline results not yet available for this target. Run the pipeline to populate.
PCSK9
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALIROCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ONGERICIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TAFOLECIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| EVOLOCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-7652 | ↓ inhibits | Mechanistic | DGIdb | |
| BOCOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FROVOCIMAB | ? unclear | Mechanistic | DGIdb | |
| RALPANCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LERODALCIBEP | ↓ inhibits | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| DIPHENYL BORINIC ACID | ↓ inhibits | Mechanistic | 30000.0 nM (Ki) | ChEMBL |
| PHENYL BUTYL BORINIC ACID | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | ChEMBL |
| CHEMBL4107804 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL4107907 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4114159 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4108338 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4107714 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4110311 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL4107559 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL4114106 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4109097 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL4108330 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL4109114 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| CHEMBL3961039 | ↓ inhibits | Mechanistic | 7300.0 nM (IC50) | ChEMBL |
| CHEMBL4112247 | ↓ inhibits | Mechanistic | 10700.0 nM (IC50) | ChEMBL |
| CHEMBL4109308 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4109014 | ↓ inhibits | Mechanistic | 11820.0 nM (IC50) | ChEMBL |
| CHEMBL4108567 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL4111131 | ↓ inhibits | Mechanistic | 18000.0 nM (IC50) | ChEMBL |
| CHEMBL4115372 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4106481 | ↓ inhibits | Mechanistic | 3050.0 nM (IC50) | ChEMBL |
| CHEMBL4108186 | ↓ inhibits | Mechanistic | 5610.0 nM (IC50) | ChEMBL |
| CHEMBL4115360 | ↓ inhibits | Mechanistic | 5800.0 nM (IC50) | ChEMBL |
| CHEMBL4114503 | ↓ inhibits | Mechanistic | 25300.0 nM (IC50) | ChEMBL |
| CHEMBL4108540 | ↓ inhibits | Mechanistic | 2970.0 nM (IC50) | ChEMBL |
| CHEMBL4109409 | ↓ inhibits | Mechanistic | 5750.0 nM (IC50) | ChEMBL |
| CHEMBL4109932 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
| CHEMBL4106569 | ↓ inhibits | Mechanistic | 16800.0 nM (IC50) | ChEMBL |
Showing top 40 of 170 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints. In the subgroup of STEMI patients with MVD, a sub-r...
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction (AMI). The main objectives are to compare Willem™ performance to detec...
This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock. An individualized transfusion strategy based on ScVO2 level, is compared to a c...
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th...
The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe tool as compared with CPET for exercise prescription in patients who have undergone CABG or PCI and enrolled in a home-based CR program with virtual exercise training monitoring.
Coronary revascularization, such as heart bypass surgery (CABG) and percutaneous coronary intervention (PCI \[inserting a stent to open up blood vessels\]) improve survival for people with coronary artery disease. Yet, many patients suffer from poor physical and mental health after coronary revascul...
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will...
The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.
aim of this study was to evaluate the relationship between multiple conventional and novel anthropometric measurements and hypertension in patients presenting to the ED with ACS and whether anthropometric indices differ according to admission BP status and evaluated the relationship between regional...
Background: Family members (spouses, siblings, offspring) of patients with coronary heart disease (CHD) may themselves be at increased risk for developing CHD for genetic, biochemical and/or behavioural reasons. Targeted approaches aimed at family members of those with established CHD may be a cost-...
Title: Evaluating New Radiation Techniques for Cardiovascular Imaging Background: Cardiac CT angiography is associated with radiation exposure. Different methods of creating CT pictures have been developed to reduce the radiation dose to the subject. The purpose of this research study is to learn ...
A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physica...
The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a place...
A randomized control trial is planned to evaluate an interactive voice response (IVR) mediated follow-up and triage system, against usual care, to help smokers hospitalized with Coronary Heart Disease (CHD) to quit smoking. The investigators hypothesize that compared to usual care, participants in t...
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Searched directly from “Ischemic Heart Disease / Coronary Artery Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."